Does PSA screening actually reduce the chance of dying from prostate cancer?
Yes, but the benefit is modest. The strongest evidence comes from the European Randomized Study of Screening for Prostate Cancer (ERSPC), which pooled data from multiple countries. After 13 years of follow-up, it found a 21% reduction in prostate cancer deaths among men invited for screening, and a 27% reduction when looking only at men who actually attended screening [7]. The CAP trial in the UK, which gave men a single PSA test, found a smaller 8% reduction in prostate cancer deaths after 15 years [1]. The difference in results is likely because the ERSPC offered repeat screening every 2-4 years, while CAP offered only one test.
The absolute numbers matter more than percentages. In the CAP trial, the death rate was 0.69% in the screened group versus 0.78% in the control group — that's about 1 fewer death per 1,000 men screened over 15 years [1]. In the ERSPC, the absolute reduction was about 1.8 fewer deaths per 1,000 men [3]. So while the relative risk reduction sounds impressive, the chance that screening will save your life is small.
Importantly, screening does not reduce your overall risk of dying from any cause. The CAP trial found no difference in all-cause mortality between the screened and unscreened groups [1]. This means that for most men, the small reduction in prostate cancer deaths is offset by other causes of death.
Who benefits most, and what are the trade-offs?
The benefit of screening is not the same for everyone. Men aged 55-69 seem to benefit most, and the effect is larger in men who are screened regularly (every 2-4 years) rather than just once [4][7]. Black men, who have a higher risk of aggressive prostate cancer, appear to get a larger absolute benefit from screening. One modeling study estimated that annual screening of Black men starting at age 40 could reduce prostate cancer deaths by 29-31%, compared to 21-24% under historical screening patterns [6]. However, this also comes with a higher rate of overdiagnosis.
The main harm is overdiagnosis — finding cancers that would never have caused symptoms or death. The CAP trial found that screening led to more diagnoses of low-grade (Gleason score 6) and localized cancers, which are often indolent [1]. A newer Finnish trial using a more sophisticated protocol (PSA, a blood test panel, and MRI) still detected 1 extra low-grade cancer per 909 men screened [2]. Once diagnosed, many men choose treatment (surgery or radiation), which can cause impotence, incontinence, and bowel problems. The risk of overdiagnosis is higher in older men and those with other health problems.
Screening also leads to unnecessary biopsies. In the CAP trial, about 66% of men with a raised PSA had a biopsy, and many of those biopsies showed no cancer or low-risk cancer [1]. Biopsies themselves carry risks of infection, bleeding, and pain.
So, should you get screened?
There is no single right answer — it depends on your age, health, risk factors, and personal values. Current guidelines from major urology associations recommend that men aged 50-69 have a shared decision-making conversation with their doctor about screening [3]. For men at higher risk — those of African descent, those with a family history of prostate cancer, or those with BRCA2 gene mutations — screening should be considered starting at age 40-45 [3][6].
If you choose to screen, the evidence suggests that screening every 2-4 years is more effective than a single test [4]. Newer approaches that combine PSA with other blood tests (like the 4-kallikrein panel) and MRI can reduce the number of unnecessary biopsies and overdiagnosis, while still catching aggressive cancers [2][5]. These are not yet standard everywhere, but they are becoming more common.
The bottom line: PSA screening can reduce your chance of dying from prostate cancer, but the benefit is small and comes with real risks of overdiagnosis and overtreatment. It is not a simple 'yes' or 'no' — it is a personal choice that should be made with your doctor, based on your individual risk profile and how you weigh the potential benefits and harms.
About These Sources
This answer is built on 7 peer-reviewed studies — published from 2018 to 2024, 4 from 2024 or later, 3 in Q1 journals, collectively cited 210 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 53 papers retrieved from a database of over 500 million.
Sources used in this answer
Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality
In the CAP trial (a large UK randomized trial), a single PSA screening invitation reduced prostate cancer deaths by 8% after 15 years, but the absolute reduction was small (0.69% vs 0.78%) and there was no effect on all-cause mortality.
Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI
The ProScreen trial in Finland used a multi-step protocol (PSA, 4-kallikrein panel, MRI) and found that screening detected 1 extra high-grade cancer per 196 men and 1 extra low-grade cancer per 909 men, compared to no screening.
Prostate cancer: screening and early detection
A review of screening evidence concludes that PSA screening does not reduce overall mortality and leads to overdiagnosis, but that risk-adapted screening (based on age, family history, genetics, and life expectancy) is recommended by guidelines.
Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer.
Analysis of ERSPC data from Finland, the Netherlands, and Sweden found that the mortality reduction from screening varied by age and center, and was largely driven by a shift to earlier-stage disease at diagnosis.
The cost-effectiveness of prostate cancer screening using the Stockholm3 test
A cost-effectiveness analysis found that using the Stockholm3 blood test as a reflex test for men with PSA ≥2.0 ng/mL was cost-effective compared to PSA alone, reducing biopsies by 30%.
The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis
Modeling studies estimated that annual PSA screening of Black men starting at age 40 could reduce prostate cancer mortality by 29-31%, but would also increase overdiagnosis. Restricting screening to ages 45-69 reduced overdiagnosis while still achieving substantial mortality reduction.
Design-corrected variation by centre in mortality reduction in the ERSPC randomised prostate cancer screening trial.
Analysis of ERSPC data from six centers found that after correcting for study design, the efficacy of screening (in those actually screened) was a 27% reduction in prostate cancer mortality at 13 years, with variation across centers.